Development of universal antidotes to control aptamer activity

Nature Medicine

Volumn 15, Issue 10, 2009, Pages 1224-1228

  Oney, Sabah ^a,b,c,g   Lam, Ruby T S ^d   Bompiani, Kristin M ^a,b,c   Blake, Charlene M ^a,b,c   Quick, George ^a   Heidel, Jeremy D ^e   Liu, Joanna Yi Ching ^e   MacK, Brendan C ^f   Davis, Mark E ^f   Leong, Kam W ^d   Sullenger, Bruce A ^a,b,c  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d Duke University   (United States)

^e Calando Pharmaceuticals   (United States)

^f California Institute of Technology   (United States)

^g NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDOTE; APTAMER;

ANIMAL EXPERIMENT; ARTICLE; BLOOD CLOTTING; CALORIMETRY; CONTROLLED STUDY; DRUG MECHANISM; DRUG SAFETY; FEMALE; GEL ELECTROPHORESIS; IN VITRO STUDY; IN VIVO STUDY; LIGHT SCATTERING; MOUSE; NONHUMAN; NUCLEOTIDE METABOLISM; NUCLEOTIDE SEQUENCE; OLIGONUCLEOTIDE THERAPY; PRIORITY JOURNAL; THROMBOCYTE FUNCTION;

EID: 70350571814     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.1990     Document Type: Article

References (36)

1. Dyke, C.K. et al. First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity. Circulation 114, 2490-2497 (2006).
2. EyetechStudyGroup. Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina 22, 143-152 (2002).
3. EyetechStudyGroup. Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: phase II study results. Ophthalmology 110, 979-986 (2003).
4. Gilbert, J.C. et al. First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers. Circulation 116, 2678-2686 (2007).
5. Lee, J.H. et al. A therapeutic aptamer inhibits angiogenesis by specifcally targeting the heparin binding domain of VEGF165. Proc. Natl. Acad. Sci. USA 102, 18902-18907 (2005).
6. McNamara, J.O. et al. Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice. J. Clin. Invest. 118, 376-386 (2008).
7. Nimjee, S.M., Rusconi, C.P. & Sullenger, B.A. Aptamers: an emerging class of therapeutics. Annu. Rev. Med. 56, 555-583 (2005).
8. Sullenger, B.A., Gallardo, H.F., Ungers, G.E. & Gilboa, E. Overexpression of TAR sequences renders cells resistant to human immunodefciency virus replication. Cell 63, 601-608 (1990).
9. Anderson, J. et al. Safety and effcacy of a lentiviral vector containing three anti-HIV genes-CCR5 ribozyme, tat-rev siRNA, and TAR decoy-in SCID-hu mouse-derived T cells. Mol. Ther. 15, 1182-1188 (2007).
10. Ellington, A.D. & Szostak, J.W. In vitro selection of RNA molecules that bind specifc ligands. Nature 346, 818-822 (1990).
11. Tuerk, C. & Gold, L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249, 505-510 (1990).
12. Becker, R.C., Rusconi, C. & Sullenger, B. Nucleic acid aptamers in therapeutic anticoagulation. Technology, development and clinical application. Thromb. Haemost. 93, 1014-1020 (2005).
13. Nimjee, S.M., Rusconi, C.P., Harrington, R.A. & Sullenger, B.A. The potential of aptamers as anticoagulants. Trends Cardiovasc. Med. 15, 41-45 (2005).
14. Fanikos, J. et al. Adverse drug events in hospitalized cardiac patients. Am. J. Cardiol. 100, 1465-1469 (2007).
15. Nimjee, S.M. et al. A novel antidote-controlled anticoagulant reduces thrombin generation and infammation and improves cardiac function in cardiopulmonary bypass surgery. Mol. Ther. 14, 408-415 (2006).
16. Rusconi, C.P. et al. RNA aptamers as reversible antagonists of coagulation factor IXa. Nature 419, 90-94 (2002).
17. Oney, S. et al. Antidote-controlled platelet inhibition targeting von Willebrand factor with aptamers. Oligonucleotides 17, 265-274 (2007).
18. Rusconi, C.P., Yeh, A., Lyerly, H.K., Lawson, J.H. & Sullenger, B.A. Blocking the initiation of coagulation by RNA aptamers to factor VIIa. Thromb. Haemost. 84, 841-848 (2000).
19. Rusconi, C.P. et al. Antidote-mediated control of an anticoagulant aptamer in vivo. Nat. Biotechnol. 22, 1423-1428 (2004).
20. Kleinman, M.E. et al. Sequence-and target-independent angiogenesis suppression by siRNA via TLR3. Nature 452, 591-597 (2008).
21. White, R. et al. Generation of species cross-reactive aptamers using "toggle" SELEX. Mol. Ther. 4, 567-573 (2001).
22. Zuker, M. Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res. 31, 3406-3415 (2003).
23. Hird, R.B. et al. Direct effects of protamine sulfate on myocyte contractile processes. Cellular and molecular mechanisms. Circulation 92, II433-II446 (1995).
24. Porsche, R. & Brenner, Z.R. Allergy to protamine sulfate. Heart Lung 28, 418-428 (1999).
25. Shigeta, O. et al. Low-dose protamine based on heparin-protamine titration method reduces platelet dysfunction after cardiopulmonary bypass. J. Thorac. Cardiovasc. Surg. 118, 354-360 (1999).
26. Welsby, I.J. et al. Hemodynamic changes after protamine administration: association with mortality after coronary artery bypass surgery. Anesthesiology 102, 308-314 (2005).
27. Gonzalez, H., Hwang, S.J. & Davis, M.E. New class of polymers for the delivery of macromolecular therapeutics. Bioconjug. Chem. 10, 1068-1074 (1999).
28. Moore, T.J., Cohen, M.R. & Furberg, CD. Serious adverse drug events reported to the Food and Drug Administration, 1998-2005. Arch. Intern. Med. 167, 1752-1759 (2007).
29. Lazarou, J., Pomeranz, B.H. & Corey, P.N. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. J. Am. Med. Assoc. 279, 1200-1205 (1998).
30. Carr, J.A. & Silverman, N. The heparin-protamine interaction. A review. J. Cardiovasc. Surg. (Torino) 40, 659-666 (1999).
31. Stanker, L.H., Wyrobek, A., McKeown, C. & Balhorn, R. Identifcation of the binding site of two monoclonal antibodies to human protamine. Mol. Immunol. 30, 1633-1638 (1993).
32. Davis, M.E. et al. Self-assembling nucleic acid delivery vehicles via linear, water-soluble, cyclodextrin-containing polymers. Curr. Med. Chem. 11, 179-197 (2004).
33. Mao, H.Q. & Leong, K.W. Design of polyphosphoester-DNA nanoparticles for non-viral gene delivery. Adv. Genet. 53, 275-306 (2005).
34. Joachimi, A., Mayer, G. & Hartig, J.S. A new anticoagulant-antidote pair: control of thrombin activity by aptamers and porphyrins. J. Am. Chem. Soc. 129, 3036-3037 (2007).
35. Schröder, M. & Bowie, A.G. TLR3 in antiviral immunity: key player or bystander? Trends Immunol. 26, 462-468 (2005).
36. Heidel, J.D. et al. Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA. Proc. Natl. Acad. Sci. USA 104, 5715-5721 (2007). 37. Harrison, P. Platelet function analysis. Blood Rev. 19, 111-123 (2005)